Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Vebreltinib Combination Therapy in MET-Overexpressing NSCLC
ChiCTR2500112942Phase 2Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of vebreltinib in non-small cell lung cancer (NSCLC) (2 cohorts), sponsored by West China Hospital of Sichuan University. Primary endpoint: Objective response rate (ORR) by investigator. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
vebreltinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2500112942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500112942.